Coronaviridae are enveloped nonsegmented, single-stranded, positive-sense RNA viruses named after their corona- or crown-like surface projections seen on electron microscopy that correspond to large surface spike proteins ([Figures 222-1](#f1){ref-type="fig"} and [222-2](#f2){ref-type="fig"} ). Coronaviruses are host-specific and can infect humans as well as a variety of different animals, causing diverse clinical syndromes.[@bib1] Three serologically and genetically distinct groups of coronaviruses have been described. Human coronaviruses (HCoV) are part of groups 1 and 2 and primarily cause a variety of respiratory tract infections[@bib1] ([Table 222-1](#cetable1){ref-type="table"} ).Figure 222-1Electron micrograph of a typical coronavirus. Negative-contrast electron micrograph of severe acute respiratory syndrome coronaviruses (SARS-CoV). The typical crown-like spike proteins on the surface of the coronavirus particles are shown. Bar = 100 nm.(From Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003;362:263--270.)Figure 222-2Pictorial illustration of a typical coronavirus. The organization of the spike (S), membrane (M), and envelope (E) glycoproteins is shown. The RNA is protected by the nucleocapsid proteins (N).Rights were not granted to include this figure in electronic media. Please refer to the printed book.(From Holmes KV, Enjuanes L. The SARS coronavirus: a postgenomic era. Science 2003;300:1377--1378.)© 20082008Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company\'s public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.TABLE 222-1Human and Representative Animal Coronaviruses (CoV)GroupCommon Name of VirusAcronymHostAssociated Diseases1Human CoV-229EHCoV-229EHumanRespiratory tract infectionHuman CoV-NL63HCoV-NL63HumanRespiratory tract infectionFeline infectious peritonitis virusFIPVCatHepatitis, respiratory tract, enteric, and neurologic infection2Human CoV-OC43HCoV-OC43HumanRespiratory tract infectionHuman CoV-HKU1HCoV-HKU1HumanRespiratory tract infection and possibly gastroenteritisSevere acute respiratory syndrome-CoV[a](#cetablefn1){ref-type="table-fn"}SARS-CoV[a](#cetablefn1){ref-type="table-fn"}HumanSevere acute respiratory syndrome (SARS)Mouse hepatitis virusMHVMouseHepatitis, encephalitis, and enteric infection3Infectious bronchitis virusIBVChickenRespiratory tract and enteric infection[^1]

EPIDEMIOLOGY {#cesec1}
============

In the 1930s, coronaviruses were recognized as disease agents in animals.[@bib2] Thirty years later, coronaviruses were identified as agents of respiratory tract infections in humans. The first recognized HCoVs included the two familiar strains, 229E and OC43, but less well-recognized strains, such as B814, OC16, OC37, and OC48, were also described.[@bib3] Due to difficulties in isolating these latter viruses in culture, they were not investigated thoroughly and to date very little is known regarding their prevalence and associated clinical illnesses. In addition to respiratory HCoVs, coronavirus-like particles have been detected in stool, primarily in infants with gastroenteritis and necrotizing enterocolitis. However, further characterization of these possible human enteric coronaviruses has been hindered primarily because of the difficulty in isolating them in culture.[@bib6]

The prevalence and associated illnesses due to HCoV 229E and OC43 have been well studied. Together, they are the second most common cause of the common cold after rhinoviruses.[@bib9] They are typically isolated in 5% to 10% of adults and 2% to 5% of children with acute upper respiratory tract infections, and 7% of children with acute otitis media.[@bib9] They are less frequent causes of lower respiratory tract infections in both adults and children.[@bib13] In temperate climates most HCoV 229E and OC43 infections occur in the winter and spring months.[@bib18] The seasonality of these infections in the tropies and subtropics has not been well defined. A rapid increase in the prevalence of antibodies to HCoV OC43 occurs after 23 months of age and almost all persons 6 years of age and older are sero-positive, suggesting that exposure to HCoV OC43 occurs in early childhood.[@bib21] [@bib22]

Most human disease caused by coronaviruses was thought to be secondary to 229E and OC43. However, in 2003, a novel HCoV was identified as the cause of the global outbreak of severe acute respiratory syndrome (SARS).[@bib23] SARS was first recognized in Guangdong province, China, in November 2002. Over the subsequent 9 months, international travel facilitated global spread to 26 countries.[@bib26] [@bib27] A total of 8098 infected people and 774 deaths were reported to the World Health Organization before the outbreak was declared over in July 2003.[@bib26] Infants and children comprised the minority of those infected.[@bib29] International cooperation and intense infection control and public health measures were critical to halting the outbreak. It is now recognized that SARS-CoV likely evolved from newly recognized animal SARS-like CoV, most frequently isolated from Himalayan civet cats and bats.[@bib30] Since the SARS outbreak was declared over, 4 isolated cases of SARS with no associated transmission were identified in China in December 2003 and January 2004.[@bib34] In addition, 2 isolated cases and one cluster of 11 cases, including 1 death, were identified in Southeast Asia related to breaches in biosafety practices in laboratories culturing SARS-CoV.[@bib35] Whether or not a large-scale re-emergence of SARS will occur is speculative.

Since the recognition of SARS-CoV, there has been renewed interest in HCoVs and novel HCoVs have subsequently been discovered. HCoV NL63 (referred to in various publications as NL and NH) was first identified by two groups in the Netherlands in a 7-month-old child with bronchiolitis and conjunctivitis, and in an 8-month old child with pneumonia.[@bib39] [@bib40] Since then HCoV NL63 has been identified in infants, children, and adults worldwide.[@bib41] Analyses of its complete genome sequence revealed that it is a new group 1 coronavirus, closely related to 229E.[@bib39] [@bib40] HCoV NL63 has been associated with upper and lower respiratory tract infections and has been found in 2% to 9% of respiratory specimens submitted to clinical laboratories that are test-negative for typical respiratory pathogens.[@bib39] [@bib47] Coinfections with other respiratory viruses are common.[@bib48] In temperate regions, HCoV NL63 appears to follow a similar seasonal pattern as 229E and OC43 with most infections occuring during winter months.[@bib39] [@bib47] Reports from Hong Kong suggest high NL63 activity may peak during its summer months.[@bib39],[@bib44],[@bib47],[@bib49] HKU1 was subsequently discovered as a novel coronavirus in Hong Kong in 2 adults with pneumonia. Analyses of its complete genome sequence revealed that it is a new group 2 coronavirus.[@bib50] It has since been identified in 2.4% of patients with community-acquired pneumonia in Hong Kong, as well as infants and small children with upper and lower respiratory tract infections worldwide.[@bib49] [@bib51] It appears to follow a similar seasonal distribution as HCoV 229E and OC43.[@bib49] [@bib51] With novel molecular methods, it would not be surprising if additional HCoVs continue to be identified in the future.[@bib55]

The modes of transmission for most HCoVs other than SARS-CoV have not been well studied. However, based on other human respiratory viruses, it is likely that transmission primarily occurs via a combination of droplet and direct and indirect contact spread.[@bib56] Which of these modes is most important remains to be determined, and the possible role of aerosol spread through talking, coughing, or sneezing needs further study. For SARS-CoV, studies suggest that droplet and direct contact spread are likely the most common modes of transmission, although evidence for indirect contact spread and aerosol spread also exists.[@bib57] There is no evidence of vertical transmission of SARS-CoV.[@bib65] [@bib66]

PATHOGENESIS AND IMMUNITY {#cesec2}
=========================

The pathogenesis of HCoVs has been best described for HCoV 229E and SARS-CoV. For SARS-CoV, most of what is understood is based on adult infections given that few children were affected during the 2002 to 2003 outbreak.[@bib29] Further studies are needed to understand further the pathogenesis of other HCoVs.

HCoV 229E and OC43 infections are initiated through inoculation of respiratory mucosal surfaces. HCoV 229E infection is associated with nasal mucosal plasma exudation and increased levels of interferon-γ in nasal lavage specimens that correlate with symptom severity.[@bib67] [@bib68] Peak viral loads in respiratory tract specimens occur within 3 days of onset of infection. Within 1 week, a dramatic reduction in viral load corresponds with symptomatic improvement.[@bib69] [@bib70] The development of antibodies, starting at 1 week, correlates with the drop in viral load.[@bib71] Antibody titers peak at about 2 weeks after onset of infection and decline slowly thereafter. Immunity is not complete and reinfection is common.[@bib71] [@bib72] Higher circulating antibody levels, and especially levels of specific IgA antibodies, correlate with reduced virus shedding and reduced symptoms upon re-exposure.[@bib71] [@bib73]

SARS-CoV infection is most likely initiated through inoculation of the respiratory tract mucosa. It is then associated with viremia followed by predominant replication in the lung and gastrointestinal tract.[@bib74] [@bib75] Replication at multiple other sites also likely occurs given the organ distribution of SARS-CoV found in tissues at autopsy.[@bib76] [@bib77] Peak viral loads in nasopharyngeal specimens are noted during the second week of symptoms.[@bib75] [@bib78] A rise in SARS-CoV-specific antibodies is typically seen starting at week 2 after infection. Increasing antibody titers during the second and third week are associated with a fall in SARS-CoV reverse transcriptase-polymerase chain reaction (RT-PCR) positivity and improvement in symptoms.[@bib78] [@bib79] Paradoxically, despite a fall in SARS-CoV viral load and a rise in SARS-specific antibodies, clinical deterioration is observed in some patients. This suggests that the host immune response is responsible for this deterioration.[@bib78] Indeed, SARS is associated with an elevation of interferon-γ, inflammatory cytokines interleukin-1, interleukin-6, and interleukin-12, as well as elevations in neutrophil chemokine interleukin-8, monocyte chemoattractant protein-1, and interferon-γ-inducible protein-10. Concentrations of interleukin-6 correlate directly with severity of disease.[@bib80] [@bib81]

CLINICAL MANIFESTATIONS {#cesec3}
=======================

HCoV 229E and OC43 {#cesec4}
------------------

HCoV 229E and OC43 are most commonly associated with upper respiratory tract infections, especially the common cold and acute otitis media.[@bib49] Common colds due to HCoV 229E are typically mild with predominant rhinorrhea.[@bib20] Colds due to HCoV OC43 are more severe and are indistinguishable from colds due to rhinoviruses; rhinorrhea, sore throat, and cough occur in approximately 50% of patients.[@bib20] Symptoms typically peak 3 to 4 days after inoculation.[@bib70] HCoV 229E and OC43 are associated with approximately 13% of asthma exacerbations.[@bib82] Less frequently, HCoV 229E and OC43 are associated with lower respiratory tract infections, including bronchiolitis, bronchitis, croup, and pneumonia -- primarily in infants and immunocompromised children and adults.[@bib13]

HCoV NL63 {#cesec5}
---------

HCoV NL63 is primarily associated with upper respiratory tract infections in infants, children, and adults. Symptoms include rhinorrhea, sore throat, and cough.[@bib40] [@bib42] [@bib47] [@bib49] In addition, HCoV NL63 is frequently associated with acute otitis media, croup, and bronchiolitis in infants and young children.[@bib47] [@bib48] Association with asthma exacerbations has been noted.[@bib49] A possible association with Kawasaki disease is controversial.[@bib83] [@bib84]

HCoV HKU1 {#cesec6}
---------

Similar to HCoV 229E, OC43, and NL63, HKU1 is primarily associated with upper respiratory tract infections in children and adults.[@bib49] An association with acute otitis media has been reported.[@bib52] HCoV HKU1 appears to be more frequently associated with febrile seizures than other coronaviruses, and in one series, children with HKU1 upper respiratory tract infections also had vomiting and diarrhea.[@bib49] [@bib52] HCoV HKU1 has been associated with bronchiolitis, asthma exacerbation, and pneumonia in children, and community-acquired pneumonia in adults.[@bib49]

SARS-CoV {#cesec7}
--------

SARS-CoV disproportionately affects adults compared with children. It causes a spectrum of illness ranging from asymptomatic infection to the severe acute respiratory syndrome, after which the virus was named.[@bib6] [@bib29] [@bib85] Patients with typical SARS become ill 2 to 10 days following exposure with fever, myalgia, headache, malaise, and chills. A nonproductive cough and dyspnea develop 3 to 5 days later, and approximately 25% of patients develop watery diarrhea. Twenty percent of patients develop worsening respiratory distress requiring intensive care support, the majority of whom require intubation and ventilation.[@bib86] The overall mortality rate is approximately 10%; most deaths occur in the third week of illness.[@bib27] [@bib89] The case-fatality rate in persons \>60 of age approaches 50%.[@bib90] Typical laboratory abnormalities include lymphopenia, and increased lactate dehydrogenase and creatinine kinase levels.[@bib91] [@bib92] The majority have progressive unilateral or bilateral ill-defined air-space infiltrates on chest imaging.[@bib91] [@bib93] Cavitation, lymphadenopathy, and pleural effusions are not typical. Pneumothoraces and other signs of barotrauma are common in critically ill patients receiving mechanical ventilation.[@bib87]

Infants and children appear to be protected against contracting the infection, and clinical manifestations in those affected are less severe. Notably, no infants or children died due to SARS-CoV infection during the 2002 to 2003 outbreak.[@bib29] [@bib96] Infants and children \<12 years old who develop SARS typically have fever, cough, and rhinorrhea. Associated lymphopenia is less severe and radiographic changes are milder and generally resolve more quickly than in adolescents and adults. Adolescents who developed SARS had clinical courses more closely resembling that of adults, presenting with fever, myalgia, headache, and chills. They are more likely to develop dyspnea, hypoxemia, and worsening chest radiographic findings. Laboratory abnormalities are comparable to those in adults.

Women infected during pregnancy who survive have an increased risk of spontaneous miscarriage, preterm delivery, and intrauterine growth restriction.[@bib65] [@bib66] [@bib100] Two neonates born to women with SARS in the 2002 to 2003 outbreak developed gastrointestinal complications (jejunal perforation, necrotizing enterocolitis with ileal perforation) shortly after birth but neither had clinical evidence of SARS-CoV.[@bib66] Whether these findings were related to complications of maternal SARS-CoV infection or treatments used during pregnancy, such as ribavirin and corticosteroids, is not clear.

DIAGNOSIS {#cesec8}
=========

The diagnosis of HCoV infections has not been attempted in clinical settings outside outbreak situations or epidemiologic surveys. However, given renewed interest in better understanding of the etiology of respiratory tract infections since the 2002 to 2003 SARS outbreak, increasing numbers of clinical laboratories are offering comprehensive respiratory diagnostic tests, including coronavirus diagnostics. Previously, diagnosis of HCoVs was based on culture, using cell lines or organs, and serologic testing by various means.[@bib20] However, more recently, direct detection of HCoVs using RT-PCR has become the standard diagnostic test, especially given the difficulty with culturing some coronaviruses and the increased sensitivity of RT-PCR.[@bib49] [@bib101]

Upper and lower respiratory tract specimens are the most appropriate samples for testing.[@bib42] [@bib49] [@bib69] [@bib102] [@bib103] Stool samples are also frequently positive in patients with SARS and have been positive in some children with HCoV HKU1 infection.[@bib52] [@bib102] [@bib103] For HCoV 299E and OC43, specimens are most likely to be positive during the first few days of illness.[@bib69] For SARS-CoV, respiratory tract and stool specimens may not be positive until the second week of illness when viral loads peak.[@bib78] [@bib102] Serum samples may be positive for antibody in patients with SARS in the first week of illness.[@bib104] [@bib105] Compared with adults, infants and children with SARS-CoV infections are less likely to have positive specimens for virus consistent with the milder symptoms and presumed corresponding lower viral loads seen in this age group.[@bib96] [@bib106] The optimal time to collect specimens for HCoV NL63 and HKU1 infections needs further study.

TREATMENT {#cesec9}
=========

There have been few studies on treatment of HCoV infections because of the self-limited clinical syndromes typically associated with HCoV 229E and OC43. However, with increasing awareness of HCoVs and recent discovery of new strains infecting humans, interest in therapy is increasing. Fortunately, infections due to HCoV NL63 and HKU1, like those due to HCoV 229E and OC43, are generally self-limited and can be treated with supportive care. SARS-CoV infections are clearly different. Ribavirin, corticosteroids, type 1 interferons, convalescent plasma, and lopinavir/ritonavir have all been used to treat SARS.[@bib91] [@bib107] Despite some anecdotal reports of clinical improvement associated with ribavirin, in vitro studies suggest minimum activity.[@bib111] For most of the other treatments used, there are anecdotal reports of clinical improvement and favorable results in in vitro assays and animal models.[@bib91],[@bib107],[@bib114] However, no definitive conclusions regarding the efficacy of any of these treatments can be made. This is especially important to note because controlled studies have not been completed for any of these agents, and there are reports of patients who were treated with just supportive care who recovered uneventfully.[@bib123] Other agents have been tested since the SARS 2002 to 2003 outbreak and appear promising based on in vitro studies. These include inhibitors of viral entry, protease inhibitors, RNA interference, and glycyrrhizin.[@bib124] In the event that SARS-CoV re-emerges, clarification of the effectiveness of all of these treatments through controlled clinical trials is needed.

PREVENTION {#cesec10}
==========

The best prevention for all HCoV infections is practicing healthy hand and respiratory hygiene.[@bib125] Control of the 2002 to 2003 SARS outbreak is credited to aggressive surveillance, institution of infection control measures, including respiratory and contact precautions, and public health measures, including quarantine. If SARS-CoV re-emerges, all of these measures should be implemented quickly in an attempt to prevent a recurrent worldwide outbreak.

Other preventive measures have been assessed. Prophylactic intranasal interferon-α has been shown to reduce the duration and severity of HCoV 229E infection in research settings but has not been used clinically.[@bib126] [@bib127] Whether this may be helpful in the prevention of other HCoVs has not been evaluated. A proprietary extract of the roots of North American ginseng (*Panax quinquefolium*) has been shown to reduce the number of colds as well as the severity and duration of cold symptoms in adults when taken daily, through presumed immune stimulation.[@bib128] Whether this could result in a decrease in colds due to HCoVs has not been studied. The development of a SARS-CoV vaccine has been recognized as a priority and work completed to date has been encouraging.[@bib124]

[^1]: SARS-CoV appears to be an outlier of group 2 but some phylogenetic analyses suggest it is the first member of a fourth group of coronaviruses.[@bib132]
